Lexaria Bioscience Corp. (NASDAQ:LEXX) on Tuesday provided an update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, focusing on 4 DehydraTECH ( DHT) study arms relative to the Novo Nordisk A/S‘ (NYSE:NVO) Rybelsus (semaglutide) control study arm.“We are extremely pleased to not only have successfully achieved our primary endpoint,” stated Richard Christopher, CEO of Lexaria, “but to have also demonstrated obvious superiority in reducing unwanted side effects by as much ...

Core Insights - Lifeway Foods (NASDAQ: LWAY) stock increased by 7.8% after the company reported mixed earnings for Q3, with earnings per share at $0.23, missing the forecast of $0.28, but sales exceeded expectations at $57.1 million, surpassing the anticipated $55 million [1][3] Financial Performance - Lifeway achieved a record revenue of $57.1 million, representing a 29% year-over-year increase, marking the sixth consecutive quarter of sales growth [3] - The gross margin improved by 3 percentage points to 28.7%, and earnings per share grew by 21% [3] Market Position and Strategy - The CEO of Lifeway emphasized the company's strong position in the kefir market and plans to leverage health and wellness trends, including the rise in GLP-1 medication use and gut health awareness [4] Cash Flow Concerns - Despite sales growth, Lifeway is facing challenges in generating free cash flow (FCF), with year-to-date cash profit at approximately $1 million, a decline of over 90% from the previous year, and less than 9% of the reported $11.3 million in GAAP profit [5][7] Investment Considerations - The mixed earnings report raises questions about the stock's attractiveness, as while sales are increasing, the significant drop in cash profits suggests caution for potential investors [6][7]

Core Insights - The drug Rybelsus is the only oral GLP-1 medication available, previously approved for Type 2 diabetes treatment, and now has expanded marketing approval for additional benefits [1] Group 1 - Rybelsus is the only oral GLP-1 medication on the market [1] - The drug was initially approved for treating Type 2 diabetes [1] - Novo Nordisk has received new approval to market the drug's additional benefits [1]

Core Insights - Lexaria Bioscience Corp. has reported positive interim results from its phase 1b study GLP-1-H24-4, focusing on its DehydraTECH drug delivery platform compared to Rybelsus® [1][2] Group 1: Study Results - After 8 weeks of treatment, DehydraTECH-GLP-1 arms showed a significant reduction in adverse events (AEs) compared to Rybelsus®, with 79.2% of DHT-semaglutide patients experiencing at least one AE versus 100% for Rybelsus® [2][4] - DehydraTECH-semaglutide demonstrated a 36.5% reduction in overall AEs and a 43.5% reduction in gastrointestinal (GI) AEs compared to Rybelsus® [3][4] - The total number of AEs for DHT-semaglutide was 61, while Rybelsus® had 96 AEs, indicating a 63.5% reduction in AEs for DHT-semaglutide relative to the control [2][4] Group 2: Efficacy Metrics - The study is assessing changes in glycated hemoglobin (HbA1c) and body weight as primary efficacy endpoints [7] - After 8 weeks, DHT-semaglutide resulted in an average weight loss of -1.14 kg (-1.23%), while DHT-tirzepatide showed a weight loss of -4.14 kg (-4.23%) [9][10] - HbA1c levels decreased by -0.14% for DHT-semaglutide, with no statistically significant difference compared to Rybelsus® at this interim stage (p=0.069) [11] Group 3: Comparative Analysis - In comparison to Novo Nordisk's® STEP studies, where 88.1% of patients experienced AEs, only 79.2% of patients in the DHT-semaglutide arm experienced AEs, suggesting a potential for improved patient adherence to treatment protocols [5] - The DHT-tirzepatide arm showed a lower proportion of GI-related AEs (22%) compared to injected tirzepatide studies, which reported 40% to 50% GI-related AEs [6] Group 4: Future Outlook - Additional data from the study will be processed and may be released in the coming weeks, with final results expected near the end of 2025 [12][13] - The study is approaching the "last patient last visit" milestone and remains on schedule [13]